Patents by Inventor Joerg RIPPMANN

Joerg RIPPMANN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATIONS COMPRISING AN SSAO/VAP-1 INHIBITOR AND A SGLT2 INHIBITOR, USES THEREOF
    Publication number: 20210212968
    Abstract: The invention relates to a pharmaceutical combination according to the invention comprising an SSAO/VAP-1 inhibitor according to the formula (I) wherein R1 to R6, and X are as defined herein, and an SGLT2 inhibitor. In addition the present invention relates to methods for preventing, slowing the progression of, delaying or treating fibrotic disorders, metabolic disorders, inflammation disorders, ocular diseases, neuroinflammatory disorders or cancer in a patient in need thereof characterized in that the pharmaceutical combination according to the invention is administered to the patient.
    Type: Application
    Filed: October 16, 2017
    Publication date: July 15, 2021
    Inventors: Joerg RIPPMANN, Thomas KLEIN, Michael MARK, Eric Williams MAYOUX
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20210113561
    Abstract: The invention relates to a pharmaceutical combination according to the invention comprising an AOC3 inhibitor according to the formula (I) wherein R1 and A are as defined herein, and an SGLT2 inhibitor. In addition the present invention relates to methods for preventing, slowing the progression of, delaying or treating fibrotic disorders, metabolic disorders, inflammation disorders, ocular diseases, neuroinflammatory disorders or cancer in a patient in need thereof characterized in that the pharmaceutical combination according to the invention is administered to the patient.
    Type: Application
    Filed: April 11, 2019
    Publication date: April 22, 2021
    Inventors: Joerg RIPPMANN, Thomas KLEIN, Michael MARK, Eric Willams MAYOUX
  • Pharmaceutical composition and pharmaceutical dosage form comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof
    Publication number: 20200188337
    Abstract: The present invention relates to pharmaceutical compositions comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide having the following chemical structure or a pharmaceutically acceptable salt thereof as active pharmaceutical ingredient, particularly to pharmaceutical compositions comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide hydrochloride, to pharmaceutical dosage forms, to their preparation, their use and methods for therapeutic treatment.
    Type: Application
    Filed: February 19, 2020
    Publication date: June 18, 2020
    Inventors: Kenji EGUSA, Takuma KATAYAMA, Kazutoshi YOKOYAMA, Remko Alexander BAKKER, Ngai Hang Victor CHONG, Joerg RIPPMANN
  • Pharmaceutical composition and pharmaceutical dosage form comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof
    Patent number: 10603292
    Abstract: The present invention relates to pharmaceutical compositions comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide having the following chemical structure or a pharmaceutically acceptable salt thereof as active pharmaceutical ingredient, particularly to pharmaceutical compositions comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide hydrochloride, to pharmaceutical dosage forms, to their preparation, their use and methods for therapeutic treatment.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: March 31, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Kenji Egusa, Takuma Katayama, Kazutoshi Yokoyama, Remko Alexander Bakker, Ngai Hang Victor Chong, Joerg Rippmann
  • Pharmaceutical composition and pharmaceutical dosage form comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof
    Publication number: 20180344672
    Abstract: The present invention relates to pharmaceutical compositions comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide having the following chemical structure or a pharmaceutically acceptable salt thereof as active pharmaceutical ingredient, particularly to pharmaceutical compositions comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide hydrochloride, to pharmaceutical dosage forms, to their preparation, their use and methods for therapeutic treatment.
    Type: Application
    Filed: May 30, 2018
    Publication date: December 6, 2018
    Inventors: Kenji EGUSA, Takuma KATAYAMA, Kazutoshi YOKOYAMA, Remko Alexander BAKKER, Ngai Hang Victor CHONG, Joerg RIPPMANN
  • Pharmaceutical Composition, Methods for Treating and Uses Thereof
    Publication number: 20180104198
    Abstract: The invention relates to a pharmaceutical combination comprising an SSAO/VAP-1 inhibitor according to the formula (I) wherein R1 to R6, and X are as defined herein, and an SGLT2 inhibitor. In addition the present invention relates to methods for preventing, slowing the progression of, delaying or treating fibrotic disorders, metabolic disorders, inflammation disorders, ocular diseases, neuroinflammatory disorders or cancer in a patient in need thereof characterized in that the pharmaceutical combination according to the invention is administered to the patient.
    Type: Application
    Filed: October 16, 2017
    Publication date: April 19, 2018
    Inventors: Joerg RIPPMANN, Thomas KLEIN, Michael MARK, Eric Williams MAYOUX